

## Certificate of Analysis

### Recombinant Human Lyn Expressed in Human Cells

LynHumaXpress


Cat #: HZ-2038 Lot #: CHI-0807

**Product Description:** Recombinant full-length human LYN (Accession No: NM002350.1) with an N-terminal GST-tag, expressed in engineered human cells.

**Specific Activity:** 247U/mg, where one unit of kinase activity is equivalent to 1nmole of ATP consumed in the presence of 250 $\mu$ M SRC substrate peptide (KVEKIGEGTYGVVYK-amide) per minute at 30°C with a final ATP concentration of 80 $\mu$ M.

#### Quality Control Testing

**LYN activity Assay:** Lyn was assayed with 250 $\mu$ M SRC substrate peptide. The Lyn protein was incubated with substrate at 30°C for 15 minutes. Activity was measured and the luminescence signal was converted to ATP consumed in the reaction.



**Purity Confirmation:** Purity was assessed by SDS-PAGE and SimplyBlue SafeStaining using 2 $\mu$ g of Lyn Kinase protein. Arrow indicates the GST-fused Lyn.

**Formulation:** 5 $\mu$ g of recombinant protein in 25 $\mu$ l of 50mM Tris, pH7.4, 150mM NaCl, 5mM DTT, 1mM PMSF. Frozen solution.

**Storage and Stability:** Stable for one year at -80°C from date of shipment (Avoid repeated freezing and thawing).

#### Reference

Yamanashi, Y. et al. (1989). *Proc. Natl. Acad. Sci.* 86, 6538-6542.

Cheng, H.C. et al. (1992). *J. Biol. Chem.* 267, 9248-9256.

**Limited Use and Restrictions:** Unless otherwise stated in our catalog or other company documentation accompanying the product, products sold by HumanZyme Inc. are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, including resale or use in manufacture, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. For a complete statement of this Limited Use License and its application to drug discovery and diagnostic research please see [www.humanzyme.com](http://www.humanzyme.com).

